The ability of CMV–specific ELISPOT assay to predict outcome of low level CMV reactivation in hematopoietic cell transplant recipients | Zendy

Dimpy P. Shah | Zendy; Ella ArizaHeredia | Zendy; Firas El Chaer | Zendy; Lynn El Haddad | Zendy; Danielle El-Haddad | Zendy; Amrita Prayag | Zendy; Lior Nesher | Zendy; Katy Rezvani | Zendy; Elizabeth J. Shpall | Zendy; Roy F. Chemaly | Zendy

Open Access

The ability of CMV–specific ELISPOT assay to predict outcome of low level CMV reactivation in hematopoietic cell transplant recipients

Author(s) -

Dimpy P. Shah,

Ella ArizaHeredia,

Firas El Chaer,

Lynn El Haddad,

Danielle El-Haddad,

Amrita Prayag,

Lior Nesher,

Katy Rezvani,

Elizabeth J. Shpall,

Roy F. Chemaly

Publication year - 2016

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofw172.1845

Subject(s) - medicine , elispot , hematopoietic cell , immunology , cytomegalovirus , cytomegalovirus infections , hematopoietic stem cell transplantation , virology , transplantation , haematopoiesis , t cell , human cytomegalovirus , human immunodeficiency virus (hiv) , viral disease , stem cell , virus , immune system , biology , herpesviridae , genetics

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog